New Anti-Chemokine Oral Drug XC8 in the Treatment of Asthma Patients with Poor Response to Corticosteroids: Results of a Phase 2A Randomized Controlled Clinical Trial. (PubMed, Pulm Ther) - Oct 26, 2020 - P2 | "Given the high safety, oral route of administration, and efficacy, XC8 may provide a promising treatment option for patients with mild-to-moderate asthma."
Clinical • Journal • P2a data • Asthma • Respiratory Diseases • CCL2 • CXCL10 • IFNG
|